R&D News | pharmaphorum

News

US left with huge hydroxychloroquine stockpile after COVID-1...

The US has been left with a huge stockpile of hydroxychloroquine, after the World Health Organization abandoned research into the drug as a treatment for COVID-19.

News

Regeneron gets closer to ISA Pharma with new immuno-oncology...

Regeneron has doubled down in its ongoing collaboration with ISA Pharma, taking a bigger stake in the Dutch biotech and cueing up a third trial of their immuno-oncology combina

News

Royalty Pharma shares surge 59% after $2.2 billion IPO

Biopharma initial public offerings are back with a bang after a coronavirus pandemic lull, as Royalty Pharma raised a record-breaking $2.2 billion from the sale of 77 million s

News

scientifically visualization of a coronavirus spike protein

Lilly takes AI-selected Olumiant into phase 3 for COVID-19

Eli Lilly has enrolled the first patient into a phase 3 trial that is seeking to repurpose arthritis drug Olumiant as a treatment for people with COVID-19.

News

teenager buying drug at club during spring break party

Evidence builds for use of MDMA as PTSD therapy

MDMA has become notorious as an illegal dance drug – but the evidence supporting its approval as a treatment for post-traumatic stress disorder (PTSD) in combination with psychotherapy is m

News

UK's Imperial College begins trial of coronavirus vaccine

Researchers from Imperial College London have begun clinical trials of a new coronavirus vaccine, backed by funding from the UK government and philanthropic donations.

US left with huge hydroxychloroquine stockpile after COVID-1...

Regeneron gets closer to ISA Pharma with new immuno-oncology...

Royalty Pharma shares surge 59% after $2.2 billion IPO

Lilly takes AI-selected Olumiant into phase 3 for COVID-19

Evidence builds for use of MDMA as PTSD therapy

UK's Imperial College begins trial of coronavirus vaccine

Hengrui gets world-first okay for platelet drug hetrombopag

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks